Nektar TherapeuticsNKTR
About: Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Employees: 61
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
4,260% more call options, than puts
Call options by funds: $218K | Put options by funds: $5K
40% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 15
36% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 36
4% more funds holding
Funds holding: 139 [Q3] → 145 (+6) [Q4]
4.6% less ownership
Funds ownership: 76.64% [Q3] → 72.04% (-4.6%) [Q4]
32% less capital invested
Capital invested by funds: $183M [Q3] → $124M (-$59.3M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Jefferies Roger Song 16% 1-year accuracy 3 / 19 met price target | 170%upside $2 | Buy Upgraded | 11 Apr 2025 |
Oppenheimer Jay Olson 20% 1-year accuracy 16 / 80 met price target | 710%upside $6 | Outperform Upgraded | 14 Mar 2025 |
HC Wainwright & Co. Arthur He 9% 1-year accuracy 3 / 32 met price target | 778%upside $6.50 | Buy Reiterated | 13 Mar 2025 |
Financial journalist opinion









